A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection

Arshad, Samia; Hartman, Pamela; Zervos, Marcus J.

doi:10.1586/14787210.2014.908118

Cited by 12 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…96 There are no randomized controlled trial (RCT) data for more invasive infections, such as bacteremia, endocarditis or osteoarticular infections, however results from case reports and series are encouraging. [97][98][99][100][101][102] Likewise, ceftaroline in combination as salvage therapy has been effective in patients with persistent MRSA bacteremia. 103 Results are yet to be published from a RCT in patients with community-acquired bacterial pneumonia at risk of MRSA infection that was completed in December 2013 (Clinical-Trials.gov NCT01645735), and compared intravenous ceftaroline 600 mg 8 hourly versus intravenous ceftriaxone 2 g once daily plus intravenous vancomycin 15 mg/kg twice daily (and adjusted based on trough concentrations).…”

Section: Ceftarolinementioning

confidence: 99%

Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond

Holmes¹,

Tong

Davis

et al. 2015

Semin Respir Crit Care Med

View full text Add to dashboard Cite

There has been a welcome increase in the number of agents available for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin remains an acceptable treatment option, with moves toward individualized dosing to a pharmacokinetic/pharmacodynamic (PK/PD) target. Numerous practicalities, however, would need to be resolved before implementation. Lipoglycopeptides as a class show excellent in vitro potency. Their long half-lives and complex PKs may preclude these agents being used in critically ill patients. Anti-MRSA cephalosporins provide great promise in the treatment of MRSA. These agents, despite broad-spectrum activity, should be reserved for patients with MRSA infections as it is likely that usage will be associated with increased rates of resistance. Daptomycin is currently the only antibiotic to have shown noninferiority to vancomycin in the treatment of MRSA bacteremia. The results of an open-labeled trial to address the superiority of daptomycin compared with vancomycin in reduced vancomycin susceptibility infections are eagerly anticipated. No drug to date has shown superiority to vancomycin in the treatment of MRSA infections with the possible exception of linezolid in hospital-acquired pneumonia (HAP), making linezolid an important option in the treatment of MRSA-proven HAP. Whether these strengths and features are agent or class specific are unclear but will likely be answered with the marketing of tedizolid. There are insufficient data to recommend either quinupristin/dalfopristin or tigecycline, as first line in the treatment of severe MRSA infections. These agents however remain options in patients with no other alternatives.

show abstract

Section: Ceftarolinementioning

confidence: 99%

Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond

Holmes¹,

Tong

Davis

et al. 2015

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Ceftaroline has in vitro bactericidal activity against MDR-MRSA, has a good safety profile, and has been approved by the Food and Drug Administration for treating adults with ABSSSI and CABP (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). This report from Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) summarizes the in vitro activity of ceftaroline against S. aureus isolates collected in Latin America during 2012, including molecular characterization of isolates with reduced susceptibility to ceftaroline.…”

mentioning

confidence: 99%

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program

Biedenbach¹,

Hoban²,

Reiszner

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activities of ceftaroline and comparators, using broth microdilution, were determined against 1,066 Staphylococcus aureus isolates from hospitalized patients. Seventeen medical centers from Latin American countries contributed isolates. Methicillin-resistant S. aureus (MRSA) percentages ranged from 46% (Brazil) to 62% (Argentina). All methicillin-susceptible S. aureus (MSSA) isolates were susceptible to ceftaroline. Ceftaroline activity against MRSA varied with MIC 90 s of 0.5 (Venezuela) to 2 (Brazil, Chile, and Colombia) g/ml, which was the highest MIC value. ST-5 was the most common sequence type.

show abstract

“…Hypersensitivity occurred in 0.3%, and direct combs test seroconversion without hemolysis has been observed in 10.8% in pooled phase 3 clinical trials [3]. Off-label utility of ceftaroline for other systemic MRSA-related infections over time has shown improved outcome [4], but also brought to light case reports with rare side effects related to this novel agent [5][6][7].…”

Section: Discussionmentioning

confidence: 99%